Successful i.p. chemotherapy depends upon delivering adequate concentrations of effective agents to the intraabdominal tumour although absorption may result in a further effect via the vascular and lymphatic systems. Effective access to the tumour may be achieved by the placement of long term indwelling catheters or by repeated short term catheterization. There are methodological problems with both approaches.
Intra-abdominal adhesion formation may pose a major obstacle to therapy. Adhesions form as a result of previous surgery and as a result of the disease process. Although adequate distribution of a 21 fluid load has been demonstrated by radioisotope studies in post-operative ovarian cancer patients repeat laparotomies have demonstrated tumour sequestered by adhesions.
Other problems associated with access are maintenance of catheter flow, infection and herniation. These problems can be minimized by the lateral placement of catheters, extraperitoneal tunnelling, a large surface area of perforated segment, pelvic anchoring with omentectomy and perioperative antibiotic cover. Additionally we have found slow IP dextran infusion during the post-operative period to be beneficial in maintaining access. This approach requires carefully controlled assessment in patients with small tumour burden.
The needlescope placement of intraperitoneal catheters M.J. Hurst Walsgrave Hospital, Coventry CV2 2DX, UK.
The correct placement of a peritoneal catheter is important in peritoneal dialysis and intraperitoneal chemotherapy. A new method has been developed that utilizes a 2.2 mm diameter rigid endoscope, known as a needlescope, to visualize the peritoneum prior to catheter implantation (Handt & Ash, Persp. Peritoneal Dialysis 2, 30, 1984) .
Initial experience with this technique in the dialysis field resulted in 20 immediately functioning catheters out of 21 attempts (95%), the failed catheterisation was due to extensive intraperitoneal adhesions from previous surgery. The early post-operative complications (occurring less than 30 days post-implantation) were as follows: Leakage -4 (20%); migration from pelvis -3 (15%); intraperitoneal bleeding -2 (10%); catheter exit site infection -2 (10%); wound infection -0 (0%).
The overall catheter failure rate, for a study period of 85 patient months, was 20%. These catheters were all removed for infective complications, occurring over 30 days postimplantation.
In addition to inserting catheters, the needlescope has been used to reposition two migrated catheters. This was achieved using a pair of grasping forceps introduced via a second puncture cannula, and avoided the need for catheter replacement.
It is concluded that this method is viable for peritoneal catheter implantation and repositioning under local anaesthesia. The principal alternative method is a laparotomy, with its high incidence of leakage, and associated risks of general anaesthesia. In the last 3 years over 100 patients have been treated by us in experimental protocols, testing intraperitoneal cisplatin, carboplatin and mitoxantrone as single agents. Drugs have been instilled in the peritoneal cavity according to a strict protocol which has been developed to optimize the procedure and to minimize complications. Most patients have been treated with Tenckhoff catheter, a small cohort received a subcutaneously implanted portacath. As pharmacokinetic studies were part of our protocol, withdrawal of fluid from the abdomen was essential; this was rarely efficient via the portacath system. This led to a temporary halt so that the manufacturers could be given time to develop wider lumen systems.
Complications from the Tenckhoff catheters were frequently observed in the beginning stages. With increasing experience, however, the procedure has become manageable. Severe side effects, such as bowel perforation, bacterial peritonitis, catheter blockage due to adhesions are now seen in less than 10% of patients.
Patients with minimal residual disease ovarian cancer who had failed to achieve a complete remission on intravenous cisplatin or carboplatin combination regimes have been entered into a series of three phase I/II studies. Thirty-two patients have been treated with cisplatin 60-90mgnm-2 and 11 achieved a laparotomy proven complete remission. Eight of the 11 have subsequently relapsed, 3 remain in unmaintained CR after 2.5 years of follow up. Thirty-three patients have been treated with intraperitoneal carboplatin, dosage ranging from 200-750mgm 2, 2 patients have achieved remissions laparotomy proven, 1 CR is laparoscopy proven. Side effects from carboplatin are mainly myelosuppression and the pharmacokinetic advantage (peritoneal exposure of drug divided by plasma exposure to drug is 6-10. The same ratio is > 1,000 for mitoxantrone) 11 patients have been treated with mitoxantrone up to a maximal tolerated dose of 55mgm-2 i.p. The dose limiting toxicity is abdominal pain due to chemical peritonitis. The phase II study has been started with infusing 25-30mgm 2 i.p. because 2 complete remissions were observed out of 11 in the phase I. Remissions have also been seen in patients with breast cancer with metastasis predominantly limited to the peritoneal surface. Occasional patients have been treated with cisplatin i.p. for mesothelioma and peritoneal spread of gastric carcinoma.
Parallel studies in the rat model have been carried out to determine the penetration of platinum compounds and fluorescent compounds, using sophisticated techniques, whereby drugs can be localized and measured in the tumour. Cytotoxic levels of cisplatin have been proved to be achieved at 2 mm within a tumour nodule in this system by application of proton induced X-ray emission and confirmed by application of a polyclonal antibody to platin DNA adducts. Results of carboplatin and mitoxantrone in the rat are not yet mature enough for reporting. The intraperitoneal system remains a good model for experimental chemotherapy and immunotherapy.
Intraperitoneal chemotherapy remains an experimental technique. It should be limited to reference Centres with a large enough infrastructure (particularly nursing care) and its place in the treatment of peritoneal metastases requires to be evaluated in randomized trials compared to intravenous chemotherapy and/or radiation to the abdomen. Several biological response modifiers have now been identified and the genes for them have been cloned, meaning that adequate supplies for therapeutic trials can be produced. One possible compound with antitumour effects in vitro is tumour necrosis factor (TNF). A phase I study of human recombinant TNF has been carried out on 18 patients, treated intravenously. The compound produced febrile reactions at all doses although these were preventable by steroids and indomethacin. Doses at or above 9 x I05 units (400 ig m -2) were associated with hypotension, abnormal liver enzymes, leucopenia and mild renal impairment in a substantial proportion of patients. TNF was cleared from the plasma with a half life of -20 min, but non-linear pharmacokinetics were seen with decreased clearance at higher levels. In three patients, all with lymphoma, improvements in their tumours were recorded.
The levels achieved intravenously are somewhat lower than those associated with regression of most murine experimental tumours. The use of intraperitoneal administration may mean that high concentrations of TNF can be delivered to tumour cells on the peritoneum. Additionally there is evidence in vitro that TNF has a synergistic action with other biological response modifiers. These factors suggest that this group of compounds may have a role to play in intraperitoneal therapy.
